Explore our development

WHAT WE DO


Sustainablility

CustoMem responsibly harness nature’s capacity to make biomaterials to treat water and promote human health and environmental sustainability.

Targeted Approach

We design and manufacture sterile biomaterials, customised to application needs, to specifically bind and remove target micropollutants from wastewater.

Treating the Insufficiently met

We treat harmful micropollutants that are difficult to capture with existing technology, persistent, bio-accumulative and pose a health hazard to humans and the environment.

RECENT NEWS

Winner of Innovation Forum imagine If London Semi-finals

Cofounder awarded Royal Academy of Engineering Enterprise Fellowship

Winners of Althea Imperial Programme 2016


The Team

Image

Henrik Hagemann

CEO and Co-founder

Responsible for operation of CustoMem, prototyping of the technology, developing business models and raising investment. He has won the prestigious Royal Academy of Engineering 1851 Royal Commission Enterprise Fellowship and completed his 1st class Masters in Bioengineering at Imperial College London.

Image

Gabi Santosa

CSO and Co-founder

Utilizes her hybrid skills to coordinate business development and customer discovery with CustoMem’s product development. She completed her BSc in Biochemistry at Imperial College London.

Image

Dr. Ben Reeve

CTO

Leads technical and product development. He completed his PhD at Imperial College London with Tom Ellis in 2016 where his research focused on genetic toolkit development of non-model organisms.

Image

Shayne Petkiewicz

Biz Dev and Engineering

Uses his entrepreneurial and scientific background to ensure that business and product development efforts develop in a complementary fashion. He completed his Masters at Imperial College London and BS at UC Berkeley, both in Chemical Engineering.

Image

Amanda You

Lead Scientist

Responsible for organizing and completing collaborative projects with customers. She completed her PhD at Imperial College London with Molly Stevens where her research focused on the bio-mineralisation process using Raman & FPA-FTIR spectroscopy techniques.

Tech Products

CustoMem granular media (CGM) is a customisable, selective, sterile biomaterial. By producing granules from bottom up using biology, the added functionality is designed to tackle hazardous micropollutants such as pesticides, pharmaceuticals and high-performance chemicals with better efficiency than ion-exchange technology and Granular Activated Carbon (GAC). CGM can be further modified through synthetic attachment of contaminant-specific proprietary binding and proteins, which allows customised surface modifications for a specific pollutant and industrial water composition.

CGM can rapidly capture micropollutants (>90% in ~10 seconds) reducing concentrations to parts per trillion (ppt) levels.
CGM operates like an industrial-scale Brita-type water filter, as drop-in to existing steel tank infrastructure and requiring a smaller footprint than GAC infrastructure.
CGM production and treatment operation are low energy (<0.5 kWh/kg media and < 0.01 kWh/M3 of treated water).
CGM can run up to 1 year until fully saturated, and once saturated, can be regenerated for reuse up to 5 times.

Collaborations

If you have an industrial waste water challenge that needs solving, please don’t hesitate to contact us. We are happy to have a chat with you and see what synergies we can develop.



Interested in joining our team? We are currently hiring and are excited to hear from you. Please submit your CV to { info@customem.com } and we will get back to you if we find a match.




Timeline

CustoMem’s team first came together for the world’s biggest synthetic biology competition, iGEM, where we came 2nd out of 245 university teams in 2014. Using this success as motivation, CustoMem was incorporated in 2015 and is headquartered in London, UK.


CustoMem currently employs 4 full time employees along with multiple subcontractors. CustoMem has begun 3 commercial trials with industrial partners with more planned and have plans of installing a treatment facility on our partner’s sites in summer of 2017.



Partners

Synbicyte
Imperial College London Incubator
Royal Academy of Engineering